Insider Selling: SiBone (NASDAQ:SIBN) Insider Sells 3,311 Shares of Stock

Key Points

• SiBone insider Anthony Recupero sold 3,311 shares at an average price of $14.25, resulting in a transaction total of $47,181.75.
• The company has a market capitalization of $625.10 million and reported a negative net margin of 12.83% for the last quarter.
• Analysts have mixed ratings on SiBone, with a consensus rating of "Moderate Buy" and an average price target of $23.67.

SiBone (NASDAQ:SIBN - Get Free Report) insider Anthony Recupero sold 3,311 shares of the company's stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $14.25, for a total transaction of $47,181.75. Following the sale, the insider directly owned 271,977 shares of the company's stock, valued at $3,875,672.25. The trade was a 1.20% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

SiBone Price Performance

Shares of SiBone stock traded down $0.01 during trading hours on Monday, reaching $14.49. 446,171 shares of the company's stock were exchanged, compared to its average volume of 422,885. SiBone has a 1 year low of $11.70 and a 1 year high of $20.05. The company has a market capitalization of $625.10 million, a P/E ratio of -25.87 and a beta of 0.83. The business has a fifty day moving average of $15.76 and a two-hundred day moving average of $16.28. The company has a quick ratio of 7.00, a current ratio of 8.38 and a debt-to-equity ratio of 0.21.

SiBone (NASDAQ:SIBN - Get Free Report) last released its earnings results on Monday, August 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.05. SiBone had a negative net margin of 12.83% and a negative return on equity of 14.20%. The business had revenue of $48.63 million during the quarter, compared to analyst estimates of $48.12 million. SiBone has set its FY 2025 guidance at EPS. As a group, research analysts predict that SiBone will post -0.78 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on SIBN shares. Cantor Fitzgerald set a $25.00 price objective on shares of SiBone and gave the company an "overweight" rating in a report on Monday, August 11th. Weiss Ratings reissued a "sell (d-)" rating on shares of SiBone in a report on Saturday, September 27th. Finally, Wall Street Zen lowered shares of SiBone from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $23.67.

Institutional Trading of SiBone

Hedge funds have recently added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd acquired a new stake in SiBone in the first quarter valued at approximately $34,000. GAMMA Investing LLC lifted its position in shares of SiBone by 20,352.6% during the 1st quarter. GAMMA Investing LLC now owns 3,886 shares of the company's stock worth $55,000 after buying an additional 3,867 shares during the last quarter. State of Wyoming purchased a new stake in shares of SiBone during the 2nd quarter worth approximately $55,000. Virtus Advisers LLC purchased a new stake in shares of SiBone during the 1st quarter worth approximately $58,000. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of SiBone during the 2nd quarter worth approximately $68,000. Institutional investors and hedge funds own 98.11% of the company's stock.

SiBone Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.